Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Mar 26;92(13):e1416-e1426.
doi: 10.1212/WNL.0000000000007188. Epub 2019 Mar 1.

Muscular and extramuscular features of myositis patients with anti-U1-RNP autoantibodies

Maria Casal-Dominguez  1 , Iago Pinal-Fernandez  1 , Andrea M Corse  1 , Julie Paik  1 , Jemima Albayda  1 , Livia Casciola-Rosen  1 , Cheilonda Johnson  1 , Sonye K Danoff  1 , Lisa Christopher-Stine  1 , Eleni Tiniakou  1 , Andrew L Mammen  2
Affiliations

Muscular and extramuscular features of myositis patients with anti-U1-RNP autoantibodies

Maria Casal-Dominguez et al. Neurology. .

Abstract

Objective: To define the clinical phenotype of patients with myositis with anti-U1-ribonucleoprotein (RNP) autoantibodies.

Methods: In this longitudinal cohort study, the prevalence and severity of clinical features at disease onset and during follow-up in patients with anti-U1-RNP-positive myositis were compared to those with dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM), and the antisynthetase syndrome (AS).

Results: Twenty anti-U1-RNP-positive patients, 178 patients with DM, 135 patients with IMNM, and 132 patients with AS were included. Anti-U1-RNP-positive patients were younger (∼37 years) and more likely to be black (60%) than patients with AS, DM, or IMNM. Muscle weakness was a presenting feature in 15% of anti-U1-RNP-positive patients; 80% eventually developed weakness. Four of 7 anti-U1-RNP-positive patients had necrotizing muscle biopsies. Arthritis occurred in 60% of anti-U1-RNP-positive patients; this was increased compared to DM (18%) or IMNM (6%) (all p < 0.01). DM-specific skin features developed in 60% of anti-U1-RNP-positive patients. Interstitial lung disease (ILD) occurred in 45% of anti-U1-RNP-positive patients; fewer patients with DM (13%) and IMNM (6%) and more patients with AS (80%) developed ILD (all p < 0.01). Glomerulonephritis and pericarditis occurred in 25% and 40% of anti-U1-RNP-positive patients, respectively, but rarely in the other groups; these features occurred only in those with coexisting anti-Ro52 autoantibodies. No anti-U1-RNP patient had cancer-associated myositis or died during the study period.

Conclusions: Patients with anti-U1-RNP myositis typically present with proximal weakness and necrotizing muscle biopsies. Arthritis, dermatitis, and ILD are the most common extramuscular clinical features. Pericarditis and glomerulonephritis are uniquely found in patients with anti-U1-RNP-positive myositis.

PubMed Disclaimer

Figures

Figure
Figure. Muscle biopsy from an anti-U1-ribonucleoprotein–positive patient (hematoxylin & eosin)
The arrow shows a necrotic cell undergoing early-stage myophagocytosis. Regenerating myofibers, characterized by basophilic cytoplasm and enlarged nuclei, are indicated by the arrowheads (×200 magnification).
See this image and copyright information in PMC

References

    1. Dalakas MC. Inflammatory muscle diseases. N Engl J Med 2015;372:1734–1747. - PubMed
    1. Sharp GC, Irvin WS, Tan EM, Gould RG, Holman HR. Mixed connective tissue disease: an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med 1972;52:148–159. - PubMed
    1. De Lorenzo R, Pinal-Fernandez I, Huang W, et al. . Muscular and extramuscular clinical features of patients with anti-PM/Scl autoantibodies. Neurology 2018;90:e2068–e2076. - PMC - PubMed
    1. Rider LG, Werth VP, Huber AM, et al. . Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI). Arthritis Care Res 2011;63(suppl 11):S118–S157. - PMC - PubMed
    1. Travis WD, Costabel U, Hansell DM, et al. . An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013;188:733–748. - PMC - PubMed

Publication types

MeSH terms

Substances

Supplementary concepts